| abstract |
A pharmaceutical composition comprising a soluble soluble hyaluronidase polypeptide at human neutral pH (sHASEGP) and an anticancer agent for use in the treatment of a tumor, in which; the anticancer agent is an antibody or a gene therapy vector; and the hyaluronidase polypeptide consists of an amino acid sequence that has at least 98% amino acid sequence identity with the amino acid sequence that is exposed as amino acids 1-448 of SEQ ID NO: 4, which corresponds to amino acids 36-483 of SEQ ID NO: 1, wherein: the polypeptide contains at least one sugar moiety that is covalently linked to an asparagine (N) moiety of the polypeptide; and the polypeptide is catalytically active. |